{
    "id": 7585,
    "fullName": "JAK2 I960V",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "JAK2 I960V lies within the protein kinase domain 2 of the Jak2 protein (UniProt.org). I960V has been described as a secondary drug resistance mutation in the context of JAK2 V617F (PMID: 23009939, PMID: 21926964), but has not been biochemically characterized and therefore, its effect on Jak2 protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 3040,
                    "pubMedId": 23009939,
                    "title": "Therapy with JAK2 inhibitors for myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23009939"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3717,
        "geneSymbol": "JAK2",
        "terms": [
            "JAK2",
            "JTK10",
            "THCYT3"
        ]
    },
    "variant": "I960V",
    "createDate": "06/14/2015",
    "updateDate": "10/21/2019",
    "referenceTranscriptCoordinates": {
        "id": 150838,
        "transcript": "NM_004972",
        "gDna": "chr9:g.5090562A>G",
        "cDna": "c.2878A>G",
        "protein": "p.I960V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2418,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to AZD1480 in culture (PMID: 21926964).",
            "molecularProfile": {
                "id": 7470,
                "profileName": "JAK2 V617F JAK2 I960V"
            },
            "therapy": {
                "id": 652,
                "therapyName": "AZD1480",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2419,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Momelotinib in culture (PMID: 21926964).",
            "molecularProfile": {
                "id": 7470,
                "profileName": "JAK2 V617F JAK2 I960V"
            },
            "therapy": {
                "id": 823,
                "therapyName": "Momelotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2415,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964).",
            "molecularProfile": {
                "id": 7470,
                "profileName": "JAK2 V617F JAK2 I960V"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2417,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Inrebic (fedratinib) in culture (PMID: 21926964).",
            "molecularProfile": {
                "id": 7470,
                "profileName": "JAK2 V617F JAK2 I960V"
            },
            "therapy": {
                "id": 911,
                "therapyName": "Fedratinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2416,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Lestauranib in culture (PMID: 21926964).",
            "molecularProfile": {
                "id": 7470,
                "profileName": "JAK2 V617F JAK2 I960V"
            },
            "therapy": {
                "id": 793,
                "therapyName": "Lestaurtinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 7469,
            "profileName": "JAK2 I960V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 7470,
            "profileName": "JAK2 V617F JAK2 I960V",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 150836,
            "transcript": "NM_001322195",
            "gDna": "chr9:g.5090562A>G",
            "cDna": "c.2878A>G",
            "protein": "p.I960V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 150835,
            "transcript": "NM_001322194",
            "gDna": "chr9:g.5090562A>G",
            "cDna": "c.2878A>G",
            "protein": "p.I960V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 150837,
            "transcript": "NM_001322196",
            "gDna": "chr9:g.5090562A>G",
            "cDna": "c.2878A>G",
            "protein": "p.I960V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 150838,
            "transcript": "NM_004972",
            "gDna": "chr9:g.5090562A>G",
            "cDna": "c.2878A>G",
            "protein": "p.I960V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}